Bhumirajanagarindra Kidney Institute Hospital, Bangkok, Thailand.
The George Institute for Global Health, Hyderabad, India.
JMIR Res Protoc. 2024 Aug 16;13:e59266. doi: 10.2196/59266.
Noncommunicable diseases (NCDs), particularly diabetes and chronic kidney diseases, pose a significant health burden in Thailand, especially among socioeconomically disadvantaged populations. The existing primary health care system faces challenges in providing optimal care for NCDs due to inadequate primary care workforce. The SMARThealth program offers a technology-based solution to enhance NCD management through task-sharing among nonphysician health care workers.
This study aims to adapt and implement the SMARThealth Diabetes program in rural Thailand to improve diabetes management. The main objectives are to (1) adapt, validate, and integrate the SMARThealth Diabetes program for improving the management of type 2 diabetes mellitus at the primary health care level; and (2) to determine the feasibility and acceptability of the SMARThealth Diabetes program in rural communities of Thailand.
A pragmatic, type 2 hybrid effectiveness or implementation, parallel-group cluster randomized controlled trial of 12 months duration and involving 51 subdistrict health offices in rural communities of Kamphaeng Phet province, Thailand, will be conducted. The intervention arm will receive the SMARThealth Diabetes program, including workforce restructuring, clinical decision support system, and continuous performance monitoring, while the control arm will continue with usual practice. Data will be collected using the SMARThealth platform and will be stored on a server in Thailand. The primary outcome measure will be the change in mean hemoglobin A (HbA) measured at randomization and 12 months from randomization between the intervention and control clusters. Secondary outcomes will include the difference in change in albuminuria status, estimated glomerular filtration rate, systolic blood pressure, and low-density lipoprotein cholesterol level. The analysis for change in HbA between baseline and end of study will be performed using linear mixed models. Any imbalances between the 2 arms will be addressed by sensitivity analyses. Additionally, a mixed methods process evaluation will be conducted to assess the implementation process, that will include in-depth interviews and focus group discussions, in addition to the quantitative data collected during the implementation process. The qualitative data will be thematically analyzed to explore factors that promote or inhibit the implementation and maintenance of the program.
The data collection commenced in November 2022, and the results will be ready for publication by the first quarter of 2025. Effectiveness of the intervention package will be assessed by change in mean HbA measures, and detailed feasibility, barriers, and enablers for the implementation of the intervention will be documented through a detailed process evaluation.
The study protocol outlines a novel approach to enhancing diabetes management in rural Thailand through digital technology-based interventions that will facilitate task-sharing among health care workers. This can help inform future strategies for improving NCD care in low-resource settings globally.
Thai Clinical Trials Registry TCTR20200322006; https://www.thaiclinicaltrials.org/show/TCTR20200322006.
INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/59266.
非传染性疾病(NCDs),特别是糖尿病和慢性肾脏病,在泰国构成了重大的健康负担,尤其是在社会经济处于不利地位的人群中。现有的初级卫生保健系统由于初级卫生保健人员不足,在提供 NCD 最佳护理方面面临挑战。SMARThealth 计划提供了一种基于技术的解决方案,通过非医师卫生保健工作者之间的任务分担来加强 NCD 管理。
本研究旨在调整并在泰国农村实施 SMARThealth 糖尿病计划,以改善糖尿病管理。主要目标是:(1)调整、验证和整合 SMARThealth 糖尿病计划,以改善基层医疗保健水平的 2 型糖尿病管理;(2)确定 SMARThealth 糖尿病计划在泰国农村社区的可行性和可接受性。
将在泰国甘烹碧府农村社区的 51 个分区卫生办公室进行为期 12 个月的实用、2 型混合有效性或实施、平行组集群随机对照试验。干预组将接受 SMARThealth 糖尿病计划,包括劳动力重组、临床决策支持系统和持续绩效监测,而对照组将继续常规实践。将使用 SMARThealth 平台收集数据,并将数据存储在泰国的服务器上。主要结局指标为随机分组和随机分组后 12 个月时干预组和对照组之间平均血红蛋白 A(HbA)的变化。次要结局指标包括白蛋白尿状态、估算肾小球滤过率、收缩压和低密度脂蛋白胆固醇水平变化的差异。将使用线性混合模型分析基线和研究结束时 HbA 的变化。通过敏感性分析解决两组之间的任何不平衡。此外,还将进行混合方法的实施过程评估,以评估实施过程,包括实施过程中的深入访谈和焦点小组讨论,以及收集的定量数据。定性数据将进行主题分析,以探讨促进或抑制该计划实施和维持的因素。
数据收集于 2022 年 11 月开始,结果将于 2025 年第一季度公布。通过平均 HbA 测量值的变化来评估干预方案的有效性,并通过详细的实施过程评估记录详细的可行性、障碍和促进因素,以评估干预措施的实施。
该研究方案概述了一种通过基于数字技术的干预措施加强泰国农村地区糖尿病管理的新方法,这将有助于分担卫生工作者的任务。这可以为全球资源匮乏环境中改善 NCD 护理的未来战略提供信息。
泰国临床试验注册中心 TCTR20200322006;https://www.thaiclinicaltrials.org/show/TCTR20200322006。
国际注册报告标识符(IRRID):DERR1-10.2196/59266。